Comparison Chart Aligos Therapeutics, Inc.
Stocks
ALGS
US01626L2043
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.245 USD | -5.66% |
|
+8.21% | -32.08% |
| 08:51am | Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment | MT |
| 07-06 | Aligos Gets $25 Million Upfront Payment From Licensing Deal | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Other Biotechnology & Medical Research | -5.44% | +8.21% | -32.08% | -27.16% | -98.32% | 40.97M |  |  |  |
- Stock Market
- Stocks
- ALGS Stock
- Charts Aligos Therapeutics, Inc.
- Comparison Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
